pharmaphorum April 22, 2024
Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for rare neurological diseases.
The deal – which covers development, regulatory, and commercial milestones and an upfront payment – centres on an option taken by Ipsen on a pair of small-molecule candidates that modulate RNA. The identity of the compounds, or their target indications, has not been disclosed, but they are in early preclinical development.
Under the terms, Ipsen will take responsibility for further development and commercialisation of the two candidates after lead compounds have been validated for further development.
It is the US-Swiss biotech’s first publicly disclosed partnering deal for some time, although, it claims to...
Today's Sponsors
Today's Sponsor